4D MOLECULAR THERAPEUTICS INFDMT
ASignal's systematic analysis rates FDMT as Neutral.
Reflects the latest available analysis · analyzed Sep 23, 2026
The case on FDMT
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (251% YoY)
- High cash position ($361.33M) relative to debt ($39.22M)
- Low debt-to-equity ratio (0.10x)
- High liquidity (current ratio 8.03x)
- Price above 20-day and 50-day moving averages
- Negative profit, operating, and gross margins
- Negative free cash flow (-$90.77M)
- Negative EV/EBITDA (-2.94x)
- High valuation multiples (P/S 9.14x, P/B 2.06x)
- High beta (2.73x) indicating elevated volatility
See the full verdict on FDMT
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes FDMT
Most investors never get a second opinion, let alone several. ASignal runs FDMT past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.